Hemostemix Inc (TSE:HEM)
:HEM
Want to see TSE:HEM full AI Analyst Report?
Top Page
Hemostemix
(HEM)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.06
▼(-22.50% Downside)
Action:Reiterated
Date:05/05/26
The score is primarily weighed down by very weak financial performance (no revenue, persistent losses, negative equity, and worsening cash burn). Technicals add additional pressure given a bearish trend and negative MACD, while valuation provides limited offset because negative earnings make P/E less informative and no dividend yield is available.
Positive Factors
Clinical-stage autologous cell therapy platform
Hemostemix’s positioning as a clinical-stage developer of autologous, patient-derived cell therapies targets large unmet needs in cardiovascular and ischemic disease. Clinical-stage progress reduces early scientific risk and positions the company for milestone-driven de‑risking and potential commercialization partnerships over months.
Negative Factors
No revenue across 2020–2025
Absence of revenue over multiple years means the business lacks product commercialization and recurring cash inflows, leaving value dependent on clinical success or external financing. Persistent operating losses consume capital and maintain dependence on dilutive funding absent decisive clinical or partnership progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical-stage autologous cell therapy platform
Hemostemix’s positioning as a clinical-stage developer of autologous, patient-derived cell therapies targets large unmet needs in cardiovascular and ischemic disease. Clinical-stage progress reduces early scientific risk and positions the company for milestone-driven de‑risking and potential commercialization partnerships over months.
Read all positive factors
Hemostemix (HEM) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$11.87M
Dividend YieldN/A
Average Volume (3M)138.35K
Price to Earnings (P/E)―
Beta (1Y)0.53
Revenue GrowthN/A
EPS Growth-29.08%
CountryCA
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding197,796,450
10 Day Avg. Volume155,944
30 Day Avg. Volume138,348
Financial Highlights & Ratios
PEG Ratio-0.66
Price to Book (P/B)-2.96
Price to Sales (P/S)0.00
P/FCF Ratio-3.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hemostemix Business Overview & Revenue Model
Company Description
Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source ...
How the Company Makes Money
null...
Hemostemix Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
8
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -46.00 | -100.00 | -223.00 | -495.00 | -1.10K |
| EBITDA | -5.63M | -1.98M | -1.95M | -4.39M | -6.45M |
| Net Income | -4.71M | -2.62M | -2.50M | -5.24M | -6.29M |
Balance Sheet | |||||
| Total Assets | 846.90K | 991.86K | 313.76K | 465.35K | 563.05K |
| Cash, Cash Equivalents and Short-Term Investments | 741.72K | 705.70K | 155.42K | 135.75K | 219.44K |
| Total Debt | 3.60M | 4.94M | 4.32M | 4.13M | 1.48M |
| Total Liabilities | 5.82M | 8.20M | 7.68M | 7.23M | 5.85M |
| Stockholders Equity | -4.97M | -7.20M | -7.37M | -6.77M | -5.28M |
Cash Flow | |||||
| Free Cash Flow | -4.53M | -1.90M | -1.42M | -6.10M | -3.48M |
| Operating Cash Flow | -4.53M | -1.90M | -1.42M | -6.10M | -3.48M |
| Investing Cash Flow | -145.88K | 0.00 | 0.00 | 0.00 | 171.12K |
| Financing Cash Flow | 4.66M | 2.45M | 1.44M | 6.02M | 3.27M |
Hemostemix Technical Analysis
Negative
0.08
Price Trends
0.07
Negative
0.08
Negative
0.08
Negative
Market Momentum
>-0.01
Negative
43.90
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HEM, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.90 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:HEM.
Hemostemix Peers Comparison
UnderperformOutperform
Sector (51)
TSE:HEM
Hemostemix
0.06
-0.07
-53.85%
TSE:IOT
Innovotech
0.12
-0.08
-40.00%
TSE:BLAB
Britannia Life Sciences Inc
0.09
0.02
21.43%
TSE:PREV
PreveCeutical Medical
0.02
>-0.01
-33.33%
Hemostemix Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Hemostemix Raises $784,000 to Advance Stem Cell Therapy Commercialization
Positive
Mar 20, 2026
Hemostemix Inc. has closed the final tranche of its non-brokered private placement, raising $303,967.80 through the issuance of 2,533,065 common shares at $0.12 per share, bringing total gross proceeds from the financing to approximately $783,967....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.